Our findings showed first time showed that MYC is a direct target of curcumin in the context of both less aggressive and highly aggressive metastatic prostate cancer, further confirming the chemo-preventive and therapeutic potential curcumin in prostate cancer. The gene discussed is MYC; the disease is metastatic prostate carcinoma.